This site uses Google Analytics to track site traffic and other metrics. If you would like to allow the use of Google Analytics please click Opt In below. This will associate a cookie with your browser.
BACKGROUND: There is good evidence of selective outcome reporting in published reports of randomized trials. METHODS: We examined reporting practices for trials of gabapentin funded by Pfizer and Warner-Lambert's subsidiary, Parke-Davis (hereafter…
Based on a thorough and scientifically valid analysis of all relevant doubleblind randomized clinical trials (DBRCT), Neurontin is not an effective drug for thetreatment of neuropathic pain. My thorough review and meta-analysis of availablepublished…
